[ad_1]
Professors Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade of international trialists were honored for their work on low-dose aspirin, with the presentation of the International Aspirin Foundation’s Senior Science Award.
The award, supported by Bayer AG, was presented in a virtual ceremony, during which the winners provided historical and updated accounts of their work.
Professor Wallentin gave a presentation on low-dose aspirin in acute coronary syndrome and the findings of the RISC research group.
The influence of this work was contextualized with a 2020 review that showed recent pharmacological interventions in acute coronary syndromes.
Professor Norrving reflected on the Swedish low-dose aspirin (SALT) trial, expanding the data results over four decades, providing an up-to-date perspective on secondary prevention of low-dose aspirin in stroke.
Professor Norrving points out that this basic therapy should be available globally, as recommended by the World Health Organization.
Professor van Gijn discussed the optimal dose of aspirin to reduce the risk of TIA or non-disabling cerebral ischemia which led to the Dutch TIA study. The study showed that 30 mg equaled 300 mg in efficacy.
Professor Peter Rothwell, who worked closely with Professor Meade, gave the presentation on the two new interventions in the Thrombosis Prevention Trial (TPT).
The study showed that aspirin reduces non-fatal ischemic heart disease. The important records preserved by this study influenced cancer prevention work with aspirin, particularly CRC.
Professor Carlo Patrono presented the prizes.
Source:
The International Aspirin Foundation
.
[ad_2]
Source link
